DBV Technologies S.A. (DBVT): Price and Financial Metrics
DBVT Price/Volume Stats
| Current price | $1.33 | 52-week high | $2.37 |
| Prev. close | $1.30 | 52-week low | $1.08 |
| Day low | $1.31 | Volume | 3,086 |
| Day high | $1.33 | Avg. volume | 127,232 |
| 50-day MA | $1.53 | Dividend yield | N/A |
| 200-day MA | $1.60 | Market Cap | 255.58M |
DBVT Stock Price Chart Interactive Chart >
DBVT POWR Grades
- Stability is the dimension where DBVT ranks best; there it ranks ahead of 54.7% of US stocks.
- The strongest trend for DBVT is in Quality, which has been heading down over the past 64 days.
- DBVT's current lowest rank is in the Momentum metric (where it is better than 9.3% of US stocks).
DBVT Stock Summary
- For DBVT, its debt to operating expenses ratio is greater than that reported by just 6.6% of US equities we're observing.
- DBVT's price/sales ratio is 52.78; that's higher than the P/S ratio of 96.83% of US stocks.
- With a year-over-year growth in debt of -47.63%, DBV TECHNOLOGIES SA's debt growth rate surpasses just 6.05% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to DBV TECHNOLOGIES SA are PULM, EIGR, HYLN, MEIP, and CTMX.
- Visit DBVT's SEC page to see the company's official filings. To visit the company's web site, go to www.dbv-technologies.com.
DBVT Valuation Summary
- In comparison to the median Healthcare stock, DBVT's price/sales ratio is 1220% higher, now standing at 52.8.
- Over the past 109 months, DBVT's price/sales ratio has gone down 144.4.
Below are key valuation metrics over time for DBVT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DBVT | 2023-09-22 | 52.8 | 1.7 | -2.7 | -1.0 |
| DBVT | 2023-09-21 | 52.8 | 1.7 | -2.7 | -1.0 |
| DBVT | 2023-09-20 | 53.7 | 1.7 | -2.8 | -1.1 |
| DBVT | 2023-09-19 | 52.4 | 1.7 | -2.7 | -1.0 |
| DBVT | 2023-09-18 | 51.3 | 1.6 | -2.7 | -1.0 |
| DBVT | 2023-09-15 | 52.4 | 1.7 | -2.7 | -1.0 |
DBV Technologies S.A. (DBVT) Company Bio
DBV Technologies SA has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. The company was founded in 2002 and is based in Bagneux, France.
Latest DBVT News From Around the Web
Below are the latest news stories about DBV TECHNOLOGIES SA that investors may wish to consider to help them evaluate DBVT as an investment opportunity.
DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial ResultsMontrouge, France, July 31, 2023 DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results Received feedback from U.S. Food and Drug Administration (FDA) on DBV’s two supplemental safety studies in toddlers (ages 1 – 3 years) and children (ages 4 – 7 years).The two Phase 3 pivotal safety studies will be named COMFORT Toddlers (1 – 3 years) and COMFORT Children (4 – 7 years).COMFORT Toddlers wil |
DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate UpdateMontrouge, France, July 25, 2023 DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, July 31st, at 5:00 p.m. ET to report first half 2023 financial results and provide a corporate update. Participants may access this event via the below t |
Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights06/30/202396,250,954 Total gross of voting rights: 96,250,954 Total net* of voting rights: 96,100,982 * Net total = total number of voting rights attached to shares – shares withou |
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHFAMF Regulated InformationMontrouge, France, July 10, 2023 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of June 30, 2023: 149,972 DBV Technologi |
Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 05/31/2023 94,198,504 Total gross of voting rights: 94,198,504 Total net* of voting rights: 94,047,253 * Net total = total number of voting rights attached to shares – shares witho |
DBVT Price Returns
| 1-mo | -11.92% |
| 3-mo | -31.44% |
| 6-mo | -21.30% |
| 1-year | -33.17% |
| 3-year | -16.88% |
| 5-year | -94.08% |
| YTD | -13.07% |
| 2022 | -4.38% |
| 2021 | -38.93% |
| 2020 | -75.51% |
| 2019 | 66.67% |
| 2018 | -73.90% |
Loading social stream, please wait...